Conjunctival melanoma with orbital invasion and liver metastasis managed with systemic immune checkpoint inhibitor therapy.

Authors

Michael Chang, Thomas Jefferson UniversityFollow
Sara E Lally, Thomas Jefferson UniversityFollow
Lauren A Dalvin, Thomas Jefferson UniversityFollow
Marlana Orloff, Thomas Jefferson University, Philadelphia, PAFollow
Carol L Shields, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

12-1-2019

Comments

This article has been peer-reviewed. It is the author's final published version in the Indian Journal of Opthalmology, Volume 67, Issue 12, December 2019, Pages 2071-2073

The published version is available at http://doi.org/10.4103/ijo.IJO_663_19. Copyright © Chang et.al.

Abstract

A 60-year-old Caucasian female was referred for biopsy-proven amelanotic orbito-conjunctival melanoma. Map biopsies revealed residual invasive melanoma on the deep tarsal margin at the site of previous surgery. Repeat excisions were required after recurrence was detected following 3 months and 7 months. Positron emission tomography scan detected liver metastasis and additional orbito-conjunctival melanoma recurrence. Biomarker testing showed NRAS mutation without BRAF or c-KIT mutations and without PD-L1 expression. Systemic checkpoint inhibitor therapy was initiated with regression of both the orbito-conjunctival melanoma and liver metastasis. Invasive, non resectable orbito-conjunctival melanoma with liver metastasis can demonstrate a response to systemic checkpoint inhibitor therapy.

Recommended Citation

Chang, Michael; Lally, Sara E; Dalvin, Lauren A; Orloff, Marlana; and Shields, Carol L, "Conjunctival melanoma with orbital invasion and liver metastasis managed with systemic immune checkpoint inhibitor therapy." (2019). Wills Eye Hospital Papers. Paper 108.
https://jdc.jefferson.edu/willsfp/108

Creative Commons License

This work is licensed under a Creative Commons Attribution-Share Alike 4.0 License.

PubMed ID

31755463

Language

English